Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre, Open Label, Observational 24-Week Study to Evaluate Safety of Initiating Insulin Therapy With Levemir (Insulin Detemir) Once-Daily in Oral Antidiabetic Drug-Treated Patients With Type 2 Diabetes.

Next Previous
Search
Trial Profile

A Multicentre, Open Label, Observational 24-Week Study to Evaluate Safety of Initiating Insulin Therapy With Levemir (Insulin Detemir) Once-Daily in Oral Antidiabetic Drug-Treated Patients With Type 2 Diabetes.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin detemir (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms SOLVE
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 01 Mar 2016 Results (n=17374) of patient subgroup analysis were published in the International Journal of Clinical Practice.
    • 28 Jun 2011 Acutal patient number (n=12,989) reported at 71st Scientific Sessions of the America Diabetes Association
    • 24 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top